AI & Tech
Ten Years of MS Data Make Delay Harder to Defend
A decade of OPERA follow-up shows durable relapse and disability control with ocrelizumab, while patients who started high-efficacy therapy later never fully caught up. The escalation debate now carries a long-term cost.
The Mystery Patient Found The Gaps
Genomics Is Becoming an Acute Neurology Test
Alzheimer’s Blood Tests Are Changing Decisions, Not Just Diagnoses
Adolescent Mental Health Has a Movement Problem
Stroke Is Getting Younger While Prevention Stays Old
Plague Never Left.
Depression Is Not One Score, and TMS Proves It
Clearing Amyloid Is Not the Same as Saving Cognition
The healthcare AI race is shifting from smarter models to safer deployment
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.